Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 87 Price-to-Tangible-Book is 5.15 as of Sep. 17, 2026. GuruFocus rates DIUXF with a GF Score™ of 87/100 and a GF Value™ of $2.51. The stock has 1 warning sign investors should review. Among 507 Healthcare Providers & Services companies, Diaceutics ranks worse than 72.98% on this metric.
As of today (2026-09-17), Diaceutics's share price is $2.00. Diaceutics's Tangible Book per Share of Dec. 2025 for the quarter that ended in Dec. 2025 was $0.39. Hence, Diaceutics's Price to Tangible Book Ratio of today is 5.15.
The historical rank and industry rank for Diaceutics's Price-to-Tangible-Book or its related term are showing as below:
DIUXF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.33 Med: 3.64 Max: 5.49
Current: 5.41
During the past 10 years, Diaceutics's highest Price to Tangible Book Ratio was 5.49. The lowest was 2.33. And the median was 3.64.
DIUXF's Price-to-Tangible-Book is ranked worse than 72.98% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 2.53
vs DIUXF: 5.41
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Diaceutics Price-to-Tangible-Book Related Terms
Diaceutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Diaceutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DIUXF vs VEEV, BTSG, TEM: Price-to-Tangible-Book Comparison
For the Health Information Services subindustry, Diaceutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Price-to-Tangible-Book vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Diaceutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Diaceutics (DIUXF) has a Price-to-Tangible-Book of 5.15 as of Sep. 17, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Diaceutics and its competitors. According to the industry distribution chart, Diaceutics ranks #370 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 73%.
Is Diaceutics' Price-to-Tangible-Book too high?
Diaceutics' current Price-to-Tangible-Book is 5.15. The Healthcare Providers & Services industry median Price-to-Tangible-Book is 2.53. Diaceutics' value of 5.15 is 103.6% above this industry median. Based on the distribution chart, Diaceutics ranks #370 out of 507 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Diaceutics has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Price-to-Tangible-Book compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #370 out of 507 companies for Price-to-Tangible-Book. This places Diaceutics in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.53. Diaceutics' value of 5.15 is 103.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Healthcare Providers & Services company?
The median Price-to-Tangible-Book among Healthcare Providers & Services companies is 2.53, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Price-to-Tangible-Book of 5.15 is 103.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median Price-to-Tangible-Book is 2.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Price-to-Tangible-Book is 5.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Diaceutics (DIUXF) has a current Price-to-Tangible-Book of 5.15. The stock's GF Value™ is $2.51, compared to a current price of $2.00 — trading 20.3% below its estimated fair value. The current Price-to-Tangible-Book is 5.15 and 103.6% above the Healthcare Providers & Services industry median of 2.53. Diaceutics' overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Price-to-Tangible-Book is 5.15 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 20.3% below its estimated GF Value™ of $2.51.
Key valuation signals for DIUXF:
Price-to-Tangible-Book: 5.15
GF Value™: $2.51 vs. price of $2.00 (20.3% below fair value)
Industry Position: 103.6% above the Healthcare Providers & Services median (#370 of 507)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
87GF Score
Get the complete analysis for DIUXF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
